NOW FDA-APPROVED to treat adults with certain types of dif‌fuse large B‑cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who have received at least 2 prior therapies1

    Talk to your healthcare provider to see if XPOVIO® (selinexor) is right for you.

    Reference: 1. XPOVIO (selinexor) [package insert]. Newton, MA: Karyopharm Therapeutics Inc.; June 2020.